Reference

Last reviewed: 28 Apr 2026
Sources cited: 10
Residues: 16

Primary structure16 residues · 1,812 Da

01MetMethionine

02ArgArginine

03TrpTryptophan

04GlnGlutamine

05GluGlutamate

06MetMethionine

07GlyGlycine

08TyrTyrosine

09IleIsoleucine

10PhePhenylalanine

11TyrTyrosine

12ProProline

13ArgArginine

14LysLysine

15LeuLeucine

16ArgArginine

Nonpolar Polar Acidic Basic Aromatic Gly/Pro

MOTS-c

Last verified: 2026-04-24

At a glance


Also known as	Mitochondrial open reading frame of the 12S rRNA-c, MOTS-c, mitochondrial-derived peptide
Class	Mitochondrial-derived peptide (MDP); 16-amino-acid bioactive peptide encoded by mitochondrial DNA
Typical route	Subcutaneous injection only. Oral is not effective.
Plasma half-life	~1–2 hours (plasma); tissue-level effects and downstream signalling persist longer
Duration of effect	Biological effects (AMPK activation, gene expression) persist days after single doses
Molecular weight	1,812 Da
Sequence	Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (16 amino acids)

What it is

MOTS-c is unusual in this encyclopedia: it’s a peptide your mitochondria already produce. Encoded within the mitochondrial 12S rRNA gene, translated into a 16-amino-acid regulatory peptide, it circulates in your blood and acts on skeletal muscle, fat tissue, and other targets. Most peptides in this space are lab-designed or hormone-derived; MOTS-c is endogenous.

Discovered in 2015 by Changhan David Lee and Pinchas Cohen at USC,1 MOTS-c sits at the frontier of a new concept in physiology: mitochondrial-derived peptides (MDPs). The mitochondrial genome, long considered a leftover from ancient bacterial endosymbionts that only encodes proteins for oxidative phosphorylation, turns out to also encode tiny regulatory peptides that modulate the nucleus of the cell. MOTS-c is the most-studied of them.

It’s marketed in the biohacker space as an “exercise mimetic” — activates some of the same pathways (AMPK, insulin sensitivity, fatty acid oxidation) that exercise does. The framing is mostly accurate but heavily over-sold; see “Reasonable expectations.”

Use-cases: metabolic health (insulin sensitivity, weight management), longevity/anti-ageing, athletic performance and recovery, diabetes-adjacent interventions. Evidence quality: strongest preclinical for any peptide in this encyclopedia; human clinical evidence essentially absent.

Mechanism

MOTS-c’s mechanisms are unusually well-characterised for a biohacker-space peptide — in part because the Cohen lab has been methodical about mapping them.

AMPK activation. The core mechanism. MOTS-c activates AMP-activated protein kinase (AMPK), the master regulator of cellular energy balance. AMPK activation is exactly what metformin does, what fasting does, what exercise does. Downstream effects: increased glucose uptake, fatty acid oxidation, mitochondrial biogenesis, inhibition of energy-consuming processes like protein synthesis.2
Folate/one-carbon cycle modulation. MOTS-c acts on the folate cycle and inhibits de novo purine biosynthesis. This leads to AICAR accumulation — AICAR itself is a direct AMPK activator, which partially mediates MOTS-c’s metabolic effects.3
Nuclear translocation under stress. When cells experience metabolic stress, MOTS-c translocates to the nucleus and directly regulates gene expression by binding to transcription factors at Antioxidant Response Elements (ARE). This is unusual — a mitochondrial peptide directly influencing nuclear gene transcription.4
Skeletal muscle target specificity. MOTS-c’s effects are concentrated in skeletal muscle — increasing glucose clearance there rather than reducing hepatic glucose production. This is the opposite pattern to metformin, which acts primarily on the liver.
Myostatin pathway modulation. Reduces myostatin signalling and muscle atrophy pathways in animal models — relevant to age-related sarcopenia.5

The peptide is exercise-responsive. In humans, exercise induces a 1.6-fold increase in circulating MOTS-c and an 11.9-fold increase in skeletal muscle MOTS-c.2 MOTS-c isn’t a compound you add to your body that isn’t already there — exogenous dosing adds to an endogenous pool that you can also raise through exercise.

Routes of administration

Subcutaneous injection


Bioavailability	High; standard subQ efficiency
Onset	Metabolic effects likely within hours; measurable changes across days to weeks
Duration	Plasma short, biological effects persist 3–7 days per dose
Typical dose (this route)	5–10 mg per injection
Equipment	Insulin syringe (U-100), BAC water, alcohol wipes; larger volumes than smaller peptides
When this route makes sense	The only evidence-aligned route. All preclinical work and community use is subQ.

The only viable route. Community standard is 5 mg doses, often every 3–5 days, cycled rather than continuous. Some protocols run higher (up to 10 mg).

Oral / sublingual


Bioavailability	Essentially zero. The 16-residue peptide does not survive gut transit.
Typical dose (this route)	Not recommended
When this route makes sense	Never, practically. Some vendors sell oral MOTS-c; don’t expect effect.

MOTS-c is not GI-stable. The size and sequence make it unsuitable for oral delivery without specialised formulation (which no research-chemical supplier uses). Oral MOTS-c products are widely sold and essentially non-functional.

Intramuscular injection


Bioavailability	Similar to subQ
Onset	Similar
Typical dose (this route)	5–10 mg (same range)
When this route makes sense	Rarely used. Community preference is subQ.

IM offers no clear advantage over subQ for a peptide whose target is distributed systemically (skeletal muscle, fat).

Cross-route comparison

SubQ or nothing. Unlike BPC-157 or KPV where multiple routes have distinct use-cases, MOTS-c’s pharmacology leaves only one practical route. If you’re not willing to inject, this compound isn’t for you.

What the evidence says

Honest summary: strong preclinical evidence (Cohen lab, replicated by others); no completed human efficacy trials of native MOTS-c; one analog (CB4211) completed Phase 1 with favourable signals. The gap between animal promise and human demonstration is real.

Cohen lab foundational work:

2015 Cell Metabolism paper (Lee, Cohen et al.) — the discovery paper. Demonstrated MOTS-c regulates skeletal muscle insulin sensitivity and metabolic homeostasis. High-fat-diet mice given MOTS-c avoided diet-induced obesity and insulin resistance.4
2020 Nature Communications paper (Reynolds, Cohen et al.) — exercise-induced physical capacity paper. Demonstrated MOTS-c is induced by exercise in humans and that late-life MOTS-c treatment improves physical capacity in aged mice, with a lifespan-extension trend.2

Multiple mechanism studies have replicated the AMPK activation, folate/purine pathway effects, and nuclear translocation findings across independent labs.3 6

Ageing genetics:

An exceptionally long-lived Japanese population carries a mitochondrial DNA variant (m.1382A>C) that yields a functional variant of MOTS-c. This is provocative but correlational — no proof the MOTS-c variant causes the longevity.7

Human efficacy:

No completed human efficacy trial of native MOTS-c exists. As of April 2026, no active MOTS-c or MOTS-c analog trials are registered on ClinicalTrials.gov.
CB4211 — a MOTS-c analog developed by CohBar — completed Phase 1a/1b testing with favourable safety and encouraging trends in liver enzymes and fasting glucose. CB4211’s development was discontinued before Phase 2. This is the closest human data available.
Human association studies show circulating MOTS-c levels decrease with obesity and age, and correlate inversely with BMI and fasting insulin — but these are observational, not interventional.

Community evidence:

Community reports for MOTS-c are less voluminous than for BPC-157 or Semax, partly because the compound is newer to the research-chemical market and partly because its effects are subtle (metabolic health, not acute subjective change).
Users typically report mild improvements in exercise recovery, body composition changes over weeks, and occasionally better glucose control if they monitor it. Many report nothing subjectively perceptible — consistent with the pharmacology.

Typical use patterns

Observations, not recommendations.

Dose:

Bolus protocol (most common community pattern): 5 mg every 5 days, 4 injections over 20 days, maximum 3 cycles per year
Intermittent dosing: 5–10 mg, several times per week, for 4–8 weeks
Conservative start: 2.5 mg first dose, observe 5 days, proceed to 5 mg if tolerated
Note on units: MOTS-c is dosed in milligrams, like TB-500 — substantially larger than BPC-157 or nootropic peptides. Unit errors are possible.

Timing:

Evening, 2+ hours after last meal — common protocol, aiming to align with overnight mitochondrial repair processes
Morning — alternative protocol aiming to align with natural AMPK/insulin sensitivity rhythms
Injection timing relative to exercise: some users dose on non-training days, others on training days; no clear evidence either is better

Cycle:

Bolus cycle: 20 days on (4 injections), 4-month rest, maximum 3 cycles per year
Intermittent cycle: 4–8 weeks on, 8+ weeks off
Continuous long-term dosing is not recommended — endogenous MOTS-c suppression has not been studied but is a plausible concern

Stacking:

Commonly combined with Epithalon in longevity protocols — Epithalon for telomeres and circadian rhythm, MOTS-c for metabolic health
Sometimes stacked with Tesamorelin for body composition (lipolytic synergy, theoretical)
Thymalin or Thymosin Alpha-1 for layered longevity/immune effects
Not commonly combined with acute-healing stacks (BPC+TB); different use-case
Metformin interaction — mechanistic overlap (both activate AMPK). No documented problem, but additive effect plausible. Users on metformin should consider dose-reducing before adding MOTS-c.

For sensitive systems

MOTS-c has a relatively favourable profile for sensitive populations compared to angiogenic peptides (BPC-157, TB-500). It’s not a mast cell provoker, not histamine-active, and its mechanism (AMPK activation, metabolic regulation) is not the kind that drives initial inflammatory flares.

Start dose. 2.5 mg single injection, then observe for 5–7 days before second dose.

Ramp. Not typical for cycling compounds — rather than daily ramping, space initial doses further apart and monitor response before committing to full bolus protocol.

Expected adjustment profile:

Mild injection site reaction — 15–20% incidence; usually transient
Transient palpitations or heart rate elevation — reported by some self-experimenters; mechanism unclear (possibly related to AMPK activation affecting sympathetic tone)
Insomnia — reported in a minority of users if dosed too late in the day
Mild fever or chills — rare but reported, usually in the first 24 hours post-injection
Headache — occasional
No documented histamine/mast cell provocation — reassuring for MCAS users

What’s not normal and warrants stopping: persistent palpitations, significant blood sugar drops (especially if already on metformin or diabetes medications), severe fatigue, any new metabolic symptoms.

Why MOTS-c may be useful for sensitive systems:

Metabolic dysregulation is common in chronic illness populations — POTS, long COVID, ME/CFS, PMDD often involve insulin resistance, mitochondrial dysfunction, or energy-metabolism issues
Mitochondrial dysfunction is implicated in ME/CFS, long COVID, fibromyalgia — MOTS-c’s mitochondrial-targeted mechanism is mechanistically relevant
Low histamine provocation risk relative to most peptides
Exercise-mimetic effects are valuable for users who can’t tolerate exercise due to post-exertional malaise — though this is speculative and cannot replace actual exercise when tolerable

Important caveat for ME/CFS and post-exertional malaise:

AMPK activation is part of the normal exercise response, which is exactly the response that fails or triggers crashes in PEM
Whether MOTS-c replicates exercise benefit without triggering PEM, or whether it provokes PEM through shared mechanisms, is unknown
Start very conservatively (2.5 mg single dose, 2-week observation before second dose) if you have PEM or post-exertional crash patterns
This is a genuine unknown — not bravery or caution, just honest acknowledgement that the mechanism could go either way

What to have on hand:

Blood glucose monitoring if you’re diabetic, pre-diabetic, or on metformin
Wearable metrics (HRV, resting heart rate, sleep) — MOTS-c’s metabolic effects are easier to track through these than through subjective report

Interactions worth considering:

Metformin: shared AMPK activation pathway. Additive effect likely. Consider temporarily reducing metformin dose when adding MOTS-c, or waiting until metformin is tolerated at current dose before layering.
Berberine: similar mechanism (AMPK activation). Layering likely additive but probably safer than metformin+MOTS-c.
Insulin or insulin secretagogues: MOTS-c improves insulin sensitivity, which could increase hypoglycaemia risk in users on insulin or sulphonylureas. Monitor blood glucose carefully.
GLP-1 agonists (semaglutide, tirzepatide, retatrutide): different mechanism, no documented interaction, theoretically complementary for metabolic effects but unstudied combination
SSRIs/SNRIs: no documented interaction
LDN: no documented interaction
Beta-blockers: no direct interaction; MOTS-c’s occasional palpitation report may be attenuated

PMDD note: PMDD has documented mitochondrial and metabolic components. MOTS-c’s mechanism is mechanistically plausible for relevance but unstudied. Not a primary PMDD intervention.

Reasonable expectations

Onset. No acute subjective effect — unlike Semax (15-minute focus hit), MOTS-c is a metabolic regulator that works over timescales of days to weeks. Measurable changes in fasting glucose, HbA1c, or body composition typically require 4–8 weeks.

Response rate. Genuinely hard to estimate because effects are subtle and measurable rather than felt. Community surveys are unreliable for MOTS-c for this reason — users often can’t tell whether it’s “working.” Probably 30–50% report clear subjective benefit (usually recovery or energy); the rest see effects only on tracked metrics (HRV, glucose, body composition) or nothing.

What the literature actually supports.

AMPK activation as the core mechanism: well-established, independently replicated
Insulin sensitivity improvement in rodents: strong and replicated
Exercise performance and physical capacity in aged rodents: demonstrated in the Cohen lab 2020 paper, replicated
Lifespan extension in rodents: a trend was observed in the Cohen lab; not definitively established
Longevity in humans: association studies only (the Japanese long-lived-cohort finding). No interventional data.
Diabetes management in humans: CB4211 Phase 1 showed encouraging trends; not established

What not to expect.

Equivalence to exercise. “Exercise mimetic” is marketing shorthand. MOTS-c activates some pathways exercise does. It does not replicate cardiovascular conditioning, muscle strengthening, bone loading, neuroplasticity, or the psychosocial benefits of exercise.
Dramatic body composition change. The effects are real but modest — consistent with metformin’s effect size, not consistent with GLP-1 agonist weight loss.
Measurable lifespan benefit for healthy younger users. The rodent lifespan benefit was in aged animals. No data supports extension in healthy-young humans.
A replacement for diabetes medication. MOTS-c is not metformin; if you have Type 2 diabetes, this is not the intervention to prioritise over proven therapies.
Acute performance enhancement. This isn’t creatine, caffeine, or Semax. Don’t dose before a workout expecting a felt effect.

Cost

Approximate as of April 2026, research-chemical market, UK-focused. Vendor-neutral.


10 mg lyophilised vial	£45–80
20 mg vial (bulk)	£80–140
Cost per bolus cycle (5 mg × 4 doses = 20 mg)	~£90–140
Cost per 8-week intermittent cycle (5 mg × 2/week = 80 mg total)	~£360–560
Cost per year at bolus cadence (3 cycles × 20 mg = 60 mg)	~£270–420

MOTS-c is moderately expensive per mg. The bolus protocol (4 doses per cycle, max 3 cycles/year) keeps annual cost manageable. Intermittent weekly protocols are substantially more expensive.

Reconstitution

10 mg lyophilised MOTS-c:

Reconstitute in 2 mL bacteriostatic water → 5 mg/mL
5 mg dose = 1 mL = 100 IU on a U-100 insulin syringe (a full insulin syringe)
2.5 mg dose = 0.5 mL = 50 IU

Alternative — larger dilution for precise sub-5 mg doses:

10 mg in 5 mL BAC water → 2 mg/mL
2.5 mg dose = 1.25 mL
5 mg dose = 2.5 mL (typically split into two injections)

Open the Vial Plan calculator

Reconstituted MOTS-c is stable in BAC water, refrigerated, for ~30 days. Lyophilised MOTS-c is stable at room temperature for months. Like TB-500, avoid vigorous shaking during reconstitution — swirl gently.

Areas of concern ⚠

Endogenous feedback suppression (theoretical)

MOTS-c is a peptide your body already produces
Chronic exogenous dosing may downregulate endogenous production — this is the standard concern with any endogenous hormone or peptide replacement
This has not been studied in humans. The cycling protocol (bolus cycles with long rest periods) is partly designed to mitigate this theoretical risk
Long-term continuous dosing is explicitly not recommended at current evidence level

The gap between animal promise and human reality

MOTS-c’s animal data is among the most compelling in the longevity space
MOTS-c’s human data is almost non-existent
This gap could close favourably (effects translate) or unfavourably (effects don’t). Buying MOTS-c now is buying the promise, not the demonstrated benefit
CB4211 — the analog that completed Phase 1 — had its development discontinued. This could mean anything (strategic, financial, efficacy), but it’s not a positive signal

Hypoglycaemia risk in combination protocols

In users on insulin, sulphonylureas, or at very high doses of metformin, the additive AMPK and insulin-sensitivity effects could increase hypoglycaemia risk
Not a concern for healthy non-diabetic users
Diabetic users should monitor blood glucose carefully and potentially reduce other medication doses before adding MOTS-c

The “exercise mimetic” framing is oversold

MOTS-c activates some exercise-related pathways (AMPK, insulin sensitivity, fat oxidation)
It does not replicate exercise. Not for cardiovascular fitness, not for bone density, not for muscle strengthening (it may modestly support muscle maintenance but doesn’t build muscle without training stimulus)
Content claiming MOTS-c “replaces exercise” is wrong
Exercise also naturally raises your own MOTS-c levels — you can get this peptide endogenously by training

Long-term human safety is uncharacterised

No human has been tracked beyond 16 weeks in any study
Effects on endogenous MOTS-c production after chronic dosing: unstudied
Effects on mitochondrial function after chronic AMPK activation: unstudied
Organ-level long-term safety: essentially unstudied
Users doing >3-month continuous protocols are in uncharted territory

Reported side effects from self-experimenters

Palpitations / heart rate elevation — reported by some users; mechanism unclear
Insomnia if dosed too late
Fever/chills rare but reported in first 24h post-injection
Injection site reactions 15–20%
No serious adverse events documented

WADA status (relevant for athletes)

MOTS-c is classified as a peptide hormone/growth factor and prohibited by WADA in and out of competition
USADA has explicitly addressed MOTS-c in anti-doping context
Athletes subject to testing should treat this as prohibited

Quality and sourcing

Research-chemical MOTS-c varies in quality; independent purity verification is rare
Oral MOTS-c products are being sold and are essentially non-functional — buyers should know this
Storage: lyophilised stable at room temp; reconstituted solution refrigerated, used within 30 days; avoid vigorous agitation

Populations where caution is warranted

Type 1 diabetes — theoretical hypoglycaemia risk if AMPK activation enhances insulin effect
Type 2 diabetes on insulin or sulphonylureas — monitor blood glucose, consider medication dose adjustment
Pregnancy and breastfeeding — no data, default contraindication
ME/CFS with severe PEM — mechanism overlap with exercise response is a genuine unknown; very conservative introduction if at all
Under 18 — no data
Competitive athletes subject to WADA testing — prohibited

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Scheduled for PCAC consultation 23–24 July 2026 for potential 503A Category 1 inclusion. Currently unapproved new drug.	2026-04-24
UK (MHRA)	Not licensed. Not a controlled substance. Sold as research chemical with “not for human consumption” labelling.	2026-04-24
EU (EMA)	Not approved. Similar posture to UK.	2026-04-24
WADA (sport)	Prohibited in and out of competition (S2 category: peptide hormones, growth factors)	2026-04-24
Related analog	CB4211 (MOTS-c analog) completed Phase 1 trials; development discontinued	2026-04-24

Narrative. MOTS-c is one of seven peptides being formally evaluated at the July 2026 PCAC meeting. Outcome could meaningfully change the US regulatory status in late 2026/2027. The peptide’s WADA-prohibited status is well-established and unlikely to change. The commercial analog pathway (CB4211) has stalled.

For UK readers: MOTS-c is legally available as a research chemical from UK-based suppliers. Not a controlled substance. Personal possession is not an offence. Sale for human consumption is not permitted. WADA testing applies for athletes in tested sports.

What to track in Peptrax

MOTS-c is sold as mitochondrial and metabolic, and the people running it usually want to see something on training, energy, or body composition. The signals worth capturing align with that thesis: training notes (load, perceived effort, recovery between sessions), HRV if you wear something that measures it, energy-floor rating across the day, and body-composition markers if you have a baseline. Subjective “energy” alone is too noisy — pair it with a load or output proxy to make it useful.

Cycle structure matters because most protocols are 4–6 weeks on, 2 weeks off, and the readout is whether the post-cycle period feels different from the pre-cycle baseline. Without baseline weeks logged before the first cycle, the comparison is reconstructed rather than measured. Logging cycle dates, dose, and the specific training context (mileage, gym frequency, deload weeks) is what makes that retrospective real.

For users in tested sports, the WADA-prohibited status is the most important non-physiological field — date of last dose, planned re-test windows, and whether a sport season overlaps any cycle. The compound’s metabolite testing window is not well published, which is itself a tracking concern: a clear “do not start within X months of competition” rule, written down at cycle planning, is safer than reconstructing exposure under pressure.

For personal tracking and informational purposes only — not medical advice.